DSGN vs. GBIO, ZVRA, GALT, SBTX, ABEO, NCNA, GTHX, SKYE, RIGL, and OMER
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Generation Bio (GBIO), Zevra Therapeutics (ZVRA), Galectin Therapeutics (GALT), Silverback Therapeutics (SBTX), Abeona Therapeutics (ABEO), NuCana (NCNA), G1 Therapeutics (GTHX), Skye Bioscience (SKYE), Rigel Pharmaceuticals (RIGL), and Omeros (OMER). These companies are all part of the "pharmaceutical preparations" industry.
Design Therapeutics (NASDAQ:DSGN) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability.
Design Therapeutics' return on equity of -22.82% beat Generation Bio's return on equity.
Design Therapeutics presently has a consensus target price of $5.50, suggesting a potential upside of 46.28%. Generation Bio has a consensus target price of $8.00, suggesting a potential upside of 165.78%. Given Generation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Generation Bio is more favorable than Design Therapeutics.
56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Generation Bio shares are owned by institutional investors. 27.8% of Design Therapeutics shares are owned by insiders. Comparatively, 20.8% of Generation Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Design Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500.
Generation Bio received 27 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Generation Bio an outperform vote while only 32.14% of users gave Design Therapeutics an outperform vote.
Design Therapeutics has higher earnings, but lower revenue than Generation Bio. Design Therapeutics is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Design Therapeutics and Design Therapeutics both had 2 articles in the media. Design Therapeutics' average media sentiment score of 1.76 beat Generation Bio's score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the media.
Summary
Generation Bio beats Design Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
